Medicamen Biotech Limited (NSE:MEDICAMEQ) — Market Cap & Net Worth
Market Cap & Net Worth: Medicamen Biotech Limited (MEDICAMEQ)
Medicamen Biotech Limited (NSE:MEDICAMEQ) has a market capitalization of $48.12 Million (Rs4.45 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #22136 globally and #1222 in its home market, demonstrating a 4.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicamen Biotech Limited's stock price Rs328.05 by its total outstanding shares 13562815 (13.56 Million). Also see balance sheet size of Medicamen Biotech Limited for a full breakdown of the balance sheet.
Medicamen Biotech Limited Market Cap History: 2021 to 2026
Medicamen Biotech Limited's market capitalization history from 2021 to 2026. Data shows change from $129.59 Million to $48.12 Million (-10.00% CAGR). Also see Medicamen Biotech Limited (MEDICAMEQ) cash flow conversion for how efficiently the company converts equity into cash flow.
Medicamen Biotech Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicamen Biotech Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Medicamen Biotech Limited stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.02x
Medicamen Biotech Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Medicamen Biotech Limited's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $129.59 Million | $1.13 Billion | $121.29 Million | 0.11x | 1.07x |
| 2022 | $121.37 Million | $1.15 Billion | $148.98 Million | 0.11x | 0.81x |
| 2023 | $88.28 Million | $1.41 Billion | $148.44 Million | 0.06x | 0.59x |
| 2024 | $75.16 Million | $1.79 Billion | $109.31 Million | 0.04x | 0.69x |
| 2025 | $53.49 Million | $1.63 Billion | $71.08 Million | 0.03x | 0.75x |
| 2026 | $48.12 Million | $1.98 Billion | $96.41 Million | 0.02x | 0.50x |
Competitor Companies of MEDICAMEQ by Market Capitalization
Companies near Medicamen Biotech Limited in the global market cap rankings as of September 19, 2026. Review MEDICAMEQ goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Medicamen Biotech Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Medicamen Biotech Limited Historical Marketcap From 2021 to 2026
Between 2021 and today, Medicamen Biotech Limited's market cap moved from $129.59 Million to $ 48.12 Million, with a yearly change of -10.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs48.12 Million | -10.04% |
| 2025 | Rs53.49 Million | -28.84% |
| 2024 | Rs75.16 Million | -14.85% |
| 2023 | Rs88.28 Million | -27.27% |
| 2022 | Rs121.37 Million | -6.34% |
| 2021 | Rs129.59 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Medicamen Biotech Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.12 Million USD |
| MoneyControl | $48.12 Million USD |
| MarketWatch | $48.12 Million USD |
| marketcap.company | $48.12 Million USD |
| Reuters | $48.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-… Read more